Key Points
- CEO Xingjuan Chao sold 39,000 shares at an average price of $17.45 on March 3 for $680,550, cutting her stake to 711,164 shares (a 5.20% decline); combined with prior sales on Jan. 5 and Feb. 23, insider disposals this period total 120,084 shares for roughly $2.40 million.
- Q4 results slightly beat estimates: CeriBell reported EPS of ($0.36) vs. a ($0.43) consensus and revenue of $24.78 million vs. $23.95 million, but the company still has negative margins and analysts project -2.46 EPS for the year.
- Shares traded around $17.80 (midday), below the 50-day SMA $20.84 but above the 200-day SMA $16.42, with a market cap near $670 million; analysts' consensus is a “Moderate Buy” with a $24.67 average target.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca Robertson sold 827 shares of the business's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total value of $14,720.60. Following the completion of the transaction, the director owned 18,749 shares in the company, valued at $333,732.20. This trade represents a 4.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
CeriBell Stock Performance
CeriBell stock traded down $0.19 during mid-day trading on Friday, reaching $17.70. 172,453 shares of the company were exchanged, compared to its average volume of 347,316. The firm's 50-day simple moving average is $20.84 and its two-hundred day simple moving average is $16.42. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $24.33. The firm has a market cap of $666.23 million, a PE ratio of -12.04 and a beta of 1.12. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The business had revenue of $24.78 million during the quarter, compared to analysts' expectations of $23.95 million. Equities analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 8,735.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company's stock worth $60,000 after buying an additional 2,708 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of CeriBell by 15.5% in the fourth quarter. Invesco Ltd. now owns 12,037 shares of the company's stock valued at $264,000 after purchasing an additional 1,618 shares in the last quarter. Creek Drive Management Group LLC acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $4,253,000. nVerses Capital LLC purchased a new position in shares of CeriBell during the 4th quarter worth approximately $282,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of CeriBell during the 4th quarter worth approximately $548,000.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Canaccord Genuity Group lifted their price objective on CeriBell from $29.00 to $30.00 and gave the company a "buy" rating in a report on Wednesday, December 17th. TD Cowen reiterated a "buy" rating on shares of CeriBell in a research report on Tuesday, December 9th. Finally, BTIG Research restated a "buy" rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.67.
Read Our Latest Analysis on CeriBell
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
